Close Menu

NEW YORK (GenomeWeb) – The US Food and Drug Administration has approved Myriad Genetics' BRACAnalysis CDx for determining which HER2-negative, metastatic breast cancer patients have inherited BRCA1 and BRCA2 genetic mutations and therefore may benefit from treatment with Pfizer's Talzenna (talazoparib).

The companion diagnostic approval accompanied the regulatory approval of Pfizer's PARP inhibitor Talzenna. Talzenna is indicated as a treatment for advanced or metastatic breast cancer patients who have BRCA mutations as determined by an FDA-approved companion diagnostic.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A new blood test might be able to detect the presence of some 50 cancers, according to New Scientist.

Undark looks into how coronavirus-related shutdowns are affecting field researchers.

In PNAS this week: strategies to design DNA oligonucleotide probes for bacteria, Vibrio cholerae evolution in Haiti, and more.

NPR reports that graduate students in the US are helping with SARS-CoV-2 testing.